AirSculpt Technologies, Inc.

AI-generated fair value estimate for this company.

Method: 5-year unlevered FCF DCF starting from normalized annual FCF of 8.0 million growing 3% per year discounted at 12%, 2% terminal growth, giving an enterprise value of about 82.5M, minus net debt of 54.33M (71.02M total debt minus 16.69M cash), divided by 72.10M shares outstanding.

Reasoning: AirSculpt is a cash-pay elective body-contouring clinic operator whose revenue fell 15.8% in FY2025 to 151.8M amid consumer softness and GLP-1 weight-loss drug competition, and although TTM free cash flow turned positive at 6.95M as clinic capex was cut sharply, the 71M of debt against modest cash generation leaves little residual equity value under conservative assumptions.